Clinical Trials Logo
  1. Home
  2. Advanced Colorectal Cancer
  3. NCT02227667

Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer

Advanced Colorectal Cancer Clinical Trial

Official title:
Phase II Study to Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer

Clinical Trial Summary

The purpose of this study is to find out what effects, good and/or bad, MEDI4736 has on the patient and cancer. MEDI4736 is a type of medication called an antibody. Antibodies are normal proteins in the body that help fight infections and possibly cancer. MEDI4736 is a special type of an antibody produced in a laboratory. MEDI4736 works by blocking a specific protein called the Programmed Death Ligand-1 (PDL-1), located on tumor cells.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02227667
Study type Interventional
Source Memorial Sloan Kettering Cancer Center
Contact
Status Completed
Phase Phase 2
Start date December 2, 2014
Completion date June 29, 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05028933 - IMC001 for Clinical Research on Advanced Digestive System Malignancies Phase 1
Recruiting NCT06200363 - A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer Phase 1
Not yet recruiting NCT02923622 - Efficacy and Safety Evaluation of Traditional Chinese Medicine in the Treatment of Advanced Colorectal Cancer N/A
Completed NCT01723969 - Screening Platform for Clinical Trials in Advanced Colorectal Cancer
Active, not recruiting NCT00309179 - A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors Phase 2
Completed NCT03699111 - Identification of New Patient Stratification Tools in MSS RAS mt mCRC
Not yet recruiting NCT02826837 - LEAC-102 for Advanced Colorectal Cancer Phase 1/Phase 2
Recruiting NCT05077839 - Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC Phase 2
Recruiting NCT04324476 - A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer Phase 2
Not yet recruiting NCT06369259 - Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer Phase 2
Completed NCT00707889 - Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer Phase 2
Terminated NCT01271166 - Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer Phase 1
Completed NCT00386828 - Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial Phase 2
Recruiting NCT04764006 - Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study Phase 2
Active, not recruiting NCT04835324 - Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study
Active, not recruiting NCT02619435 - Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer Phase 2
Completed NCT01822444 - ANGIOPREDICT. ICORG 12-16, V3
Completed NCT00498407 - A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer Phase 2
Recruiting NCT05731336 - A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan.
Active, not recruiting NCT04744831 - Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer Phase 2